Life Science Investing Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
Life Science Investing Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
Life Science Investing Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
Life Science Investing Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
